Episode 8 John Leonard CEO of Intellia Therapeutics

John Leonard, CEO of Intellia Therapeutics, boasts over 30 years in drug research and development. He discusses Intellia's inception and the challenges faced during the launch of genome editing programs. Insights into the ethical concerns surrounding biotechnology are explored, with a focus on gene editing implications. Leonard also reflects on the competitive landscape of the CRISPR sector and emphasizes the importance of making genetic therapies accessible and affordable for patients. His experiences and commitment highlight the evolving landscape of biotech.